Lyra Therapeutics Inc. (LYRA)
Lyra Therapeutics Statistics
Share Statistics
Lyra Therapeutics has 65.46M shares outstanding. The number of shares has increased by 9.57% in one year.
| Shares Outstanding | 65.46M |
| Shares Change (YoY) | 9.57% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 49.7% |
| Shares Floating | 54.51M |
| Failed to Deliver (FTD) Shares | 11.84K |
| FTD / Avg. Volume | 0.9% |
Short Selling Information
The latest short interest is 2.13M, so 3.26% of the outstanding shares have been sold short.
| Short Interest | 2.13M |
| Short % of Shares Out | 3.26% |
| Short % of Float | 3.98% |
| Short Ratio (days to cover) | 1.09 |
Valuation Ratios
The PE ratio is -4.16 and the forward PE ratio is -0.19. Lyra Therapeutics's PEG ratio is 0.13.
| PE Ratio | -4.16 |
| Forward PE | -0.19 |
| PS Ratio | 167.51 |
| Forward PS | 0.2 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -4.06 |
| PEG Ratio | 0.13 |
Enterprise Valuation
Lyra Therapeutics Inc. has an Enterprise Value (EV) of 287.86M.
| EV / Earnings | -4.59 |
| EV / Sales | 184.76 |
| EV / EBITDA | -4.41 |
| EV / EBIT | -4.29 |
| EV / FCF | -4.47 |
Financial Position
The company has a current ratio of 5.35, with a Debt / Equity ratio of 0.3.
| Current Ratio | 5.35 |
| Quick Ratio | 5.35 |
| Debt / Equity | 0.3 |
| Total Debt / Capitalization | 23.11 |
| Cash Flow / Debt | -2.35 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.7% and return on capital (ROIC) is -57.77%.
| Return on Equity (ROE) | -0.7% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -57.77% |
| Revenue Per Employee | 17.7K |
| Profits Per Employee | -712.27K |
| Employee Count | 88 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 59K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -96.31% in the last 52 weeks. The beta is -0.13, so Lyra Therapeutics's price volatility has been lower than the market average.
| Beta | -0.13 |
| 52-Week Price Change | -96.31% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 61.4 |
| Average Volume (20 Days) | 1.31M |
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.56M and earned -62.68M in profits. Earnings per share was -1.26.
| Revenue | 1.56M |
| Gross Profit | 1.56M |
| Operating Income | -67.12M |
| Net Income | -62.68M |
| EBITDA | -65.25M |
| EBIT | -67.12M |
| Earnings Per Share (EPS) | -1.26 |
Balance Sheet
The company has 22.35M in cash and 26.88M in debt, giving a net cash position of -4.53M.
| Cash & Cash Equivalents | 22.35M |
| Total Debt | 26.88M |
| Net Cash | -4.53M |
| Retained Earnings | -311.36M |
| Total Assets | 78.76M |
| Working Capital | 39.49M |
Cash Flow
In the last 12 months, operating cash flow was -63.3M and capital expenditures -1.05M, giving a free cash flow of -64.35M.
| Operating Cash Flow | -63.3M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -64.35M |
| FCF Per Share | -1.29 |
Margins
Gross margin is 100%, with operating and profit margins of -4.31K% and -4.02K%.
| Gross Margin | 100% |
| Operating Margin | -4.31K% |
| Pretax Margin | -4.02K% |
| Profit Margin | -4.02K% |
| EBITDA Margin | -4.19K% |
| EBIT Margin | -4.31K% |
| FCF Margin | -4.13K% |
Dividends & Yields
LYRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -600% |
| FCF Yield | -463.72% |
Analyst Forecast
The average price target for LYRA is $2, which is 852.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 852.4% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -9.07 |
| Piotroski F-Score | 3 |